## Abstract The heat shock proteins are families of proteins with known activities that include chaperoning nascent peptides within the cell and cytoprotection. Most work on the nervous system has related to the role of heat shock proteins in neuroprotection from either hypoxic‐ischemic or traumati
Nuclear envelope proteins and neuromuscular diseases
✍ Scribed by Cecilia Östlund; Howard J. Worman
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 593 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0148-639X
No coin nor oath required. For personal study only.
✦ Synopsis
Several neuromuscular diseases are caused by mutations in emerin and A-type lamins, proteins of the nuclear envelope. Emery-Dreifuss muscular dystrophy is caused by mutations in emerin (X-linked) or A-type lamins (autosomal dominant). Mutations in A-type lamins also cause limb-girdle muscular dystrophy type 1B, dilated cardiomyopathy with conduction defect, and Charcot-Marie-Tooth disorder type 2B1. They also cause partial lipodystrophy syndromes. The functions of emerin and A-type lamins and the mechanisms of how mutations in these proteins cause tissue-specific diseases are not well understood. The mutated proteins may cause structural damage to cells but may also affect processes such as gene regulation. This review gives an overview of this topic and describes recent advances in identification of disease-causing mutations, studies of cells and tissues from subjects with these diseases, and animal and cell culture models.
📜 SIMILAR VOLUMES
## The nuclear envelope has recently become the object of intense scrutiny because it is the site of nuclear transport and is possibly involved in the organization of the interphase genome, thereby aflecting gene expression. The major structural support for the nuclear envelope is the nuclear lamina
An antinuclear immunofluorescence pattern displaying a thin ring confined to the nuclear envelope was assessed in sera from 38 patients with primary biliary cirrhosis and in sera from a control group of 277 patients with other antinuclear antibody-positive diseases. This rim-like antinuclear reactiv
T h e treatment of a disease may spring from an understanding of the underlying etiology of that disease, or it may arise less directly. For instance, the use of L-dopa in the treatment of Parkinson's disease arose from the finding of deficient dopamine levels in the brains o f Parkinsonian patients